NASDAQ:ERNA Ernexa Therapeutics (ERNA) Stock Price, News & Analysis $2.96 -0.24 (-7.50%) Closing price 10/1/2026 04:00 PM EasternExtended Trading$3.17 +0.21 (+6.99%) As of 09:28 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsNews and TrendsOwnershipSEC Filings About Ernexa Therapeutics Stock (NASDAQ:ERNA) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Ernexa Therapeutics alerts:Sign Up Key Stats Today's Range$2.84▼$3.2450-Day Range$2.96▼$5.0352-Week Range$2.84▼$71.50Volume35,736 shsAverage Volume47,673 shsMarket Capitalization$4.82 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingHold Company Overview Eterna Therapeutics Inc., a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited. Eterna Therapeutics Inc. was founded in 2018 and is based in Cambridge, Massachusetts. Read More Ernexa Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks68th Percentile Overall ScoreERNA MarketRank™: Ernexa Therapeutics scored higher than 68% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingErnexa Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.Upside PotentialErnexa Therapeutics has a consensus price target of $30.00, representing about 913.5% upside from its current price of $2.96.Amount of Analyst CoverageErnexa Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Ernexa Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Ernexa Therapeutics are expected to grow in the coming year, from ($18.02) to ($1.86) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Ernexa Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Ernexa Therapeutics is -0.21, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioErnexa Therapeutics has a P/B Ratio of 0.39. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Ernexa Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.88% of the float of Ernexa Therapeutics has been sold short.Short Interest Ratio / Days to CoverErnexa Therapeutics has a short interest ratio ("days to cover") of 0.21, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Ernexa Therapeutics has recently decreased by 27.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldErnexa Therapeutics does not currently pay a dividend.Dividend GrowthErnexa Therapeutics does not have a long track record of dividend growth. News and Social Media2.7 / 5News Sentiment0.33 News SentimentErnexa Therapeutics has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.48 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Ernexa Therapeutics this week, compared to 3 articles on an average week.Search Interest1 people have searched for ERNA on MarketBeat in the last 30 days. Company Ownership0.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Ernexa Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders0.53% of the stock of Ernexa Therapeutics is held by insiders.Percentage Held by Institutions70.55% of the stock of Ernexa Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Ernexa Therapeutics' insider trading history. Receive ERNA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Ernexa Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ERNA Stock News HeadlinesErnexa Therapeutics CEO Corner Highlights Appointment of Dr. Robert J. Spiegel as Company Sharpens Oncology Focus and Advances ERNA-101 Toward the ClinicOctober 1 at 9:20 AM | globenewswire.comErnexa Therapeutics Reports ERNA-101 Safety Results Across Three IND-Enabling StudiesOctober 1 at 1:06 AM | marketscreener.comMHow Elon’s Empire Ends (and how to profit)Marc Chaikin, the 60 year Wall Street veteran whose Chaikin Money Flow indicator sits on every Bloomberg terminal, says a new micro cluster AI technology could render today's data centers, including Elon Musk's Colossus in Tennessee, obsolete for major breakthroughs. These next generation centers use 99 percent less space, electricity and water, yet Chaikin's research shows they could be more than a trillion times more powerful than the top data center on earth today, potentially cutting AI breakthrough timelines from five years to five days.October 2 at 1:00 AM | Chaikin Analytics (Ad)Ernexa Reports Positive ERNA-101 Safety Data Ahead Of Q4 INDSeptember 30 at 3:01 PM | rttnews.comErnexa Therapeutics Advances ERNA-101 Toward Planned Q4 2026 INDSeptember 30 at 3:01 PM | rttnews.comErnexa Therapeutics Reports Compelling ERNA-101 Safety Results Across Three Critical IND-Enabling Studies, Advancing Toward Planned Q4 2026 INDSeptember 30 at 8:32 AM | globenewswire.comErnexa Selected For Emerging Track At 2026 Cell & Gene Meeting On The MesaSeptember 29 at 6:16 PM | rttnews.comErnexa Therapeutics Selected for Emerging Track at 2026 Cell & Gene Meeting on the Mesa, Highlighting ERNA-101 and Focused Oncology StrategySeptember 29 at 9:15 AM | globenewswire.comSee More Headlines ERNA Stock Analysis - Frequently Asked Questions How have ERNA shares performed this year? Ernexa Therapeutics' stock was trading at $30.00 at the beginning of the year. Since then, ERNA stock has decreased by 90.1% and is now trading at $2.96. How were Ernexa Therapeutics' earnings last quarter? Ernexa Therapeutics Inc. (NASDAQ:ERNA) posted its quarterly earnings results on Thursday, August, 6th. The company reported ($3.40) earnings per share for the quarter, missing the consensus estimate of ($3.30) by $0.10. When did Ernexa Therapeutics' stock split? Ernexa Therapeutics shares reverse split before market open on Monday, May 4th 2026.The 1-25 reverse split was announced on Thursday, April 30th 2026. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 1st 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. How do I buy shares of Ernexa Therapeutics? Shares of ERNA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Ernexa Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Ernexa Therapeutics investors own include Zomedica (ZOM), Jumia Technologies (JMIA), Nano Dimension (NNDM), AST SpaceMobile (ASTS), NIO (NIO), Bakkt (BKKT) and Company Calendar Last Earnings8/06/2026Today10/02/2026Next Earnings (Estimated)11/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 ERNA's financial health is in the Yellow zone, according to TradeSmith. ERNA has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:ERNA CIK748592 Webwww.ernexatx.com Phone(617) 798-6700Fax760-438-3505Employees5Year Founded1953Price Target and Rating Average Price Target for Ernexa Therapeutics$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+913.5%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($14.35) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$14.08 million Net MarginsN/A Pretax MarginN/A Return on Equity-305.93% Return on Assets-169.86% Debt Debt-to-Equity RatioN/A Current Ratio2.01 Quick Ratio2.01 Sales & Book Value Annual Sales$580 thousand Price / Sales8.32 Cash FlowN/A Price / Cash FlowN/A Book Value$7.64 per share Price / Book0.39Miscellaneous Outstanding Shares1,630,000Free Float1,623,000Market Cap$4.82 million OptionableNo Data Beta2.64 Social Links 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:ERNA) was last updated on 10/2/2026 by MarketBeat.com Staff. From Our PartnersThe rich already moved their moneyBy the time a crash hits the news, it's already too late to protect your money. Parkview Capital's free Mar...Parkview Capital Group | SponsoredMy next big call (under $1)Crypto traders have a name for this month... Uptober. Since 2013, Bitcoin has closed October higher in 10 of 1...Crypto 101 Media | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThis AI fund posted a 34 percent annualized payout last monthOne small fund tied to artificial intelligence stocks delivered $1,051 in a single month, not through selling ...Investors Alley | SponsoredThe SEC Just Opened The Floodgates…The SEC removed the 25 year old Pattern Day Trader rule in June 2026, cutting the minimum to open a trading ac...StocksToTrade | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | Sponsored"How Much Can I Actually Spend Each Year With $2.5M Saved?"Having $2.5 million saved puts you ahead of most Americans, but how long it lasts depends on the decisions you...SmartAsset | SponsoredMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...TradeSmith | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ernexa Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ernexa Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
